Dr.Kathleen Ruddy

Dr. Paul Mann - a prostate cancer patient who was told he had no hope of survival - shared his incredible story, in which he continues to recover through the use of the repurposed drug, ivermectin.

Turbo cancers are a rapidly escalating threat in the wake of the COVID pandemic, forcing doctors to push the boundaries of traditional oncology treatment. In this presentation, Dr. Kathleen Ruddy, Dr. Paul Marik, and Dr. Nathan Goodyear introduced groundbreaking adjunctive treatment strategies that are reshaping cancer care.

Paul Mann had advanced cancer, which his oncologist said was terminal. He had over a dozen radiation treatments and six rounds of chemotherapy and was put in hospice care twice. Then he met Dr. Kathleen Ruddy. Watch his hopeful MyStory filmed at the FLCCC Conference in Phoenix.

Dr. Paul Marik and Executive Director Kelly Bumann recap FLCCC's 3rd educational conference and discuss the recently launched FLCCC Observational Cancer Study.

The FLCCC Alliance is proud to announce it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in collaboration with five U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs.

A team of U.S. clinicians will participate in an observational study to determine improvements in the five-year survival rate for several types of cancer.

Dr. Kathleen Ruddy explains the difference between getting a breast thermography and a breast mammography for breast cancer screening.

Dr. Kathleen Ruddy, breast cancer surgeon and author of The End of Breast Cancer: A Virus in Hope for a Vaccine, joined Dr. Paul Marik for a discussion on 'Cancer And Repurposed Drugs'.  Dr. Ruddy will speak at FLCCC's third educational conference, 'Healthcare Revolution: Restoring the Doctor-Patient Relationship', February 2-4, 2024 in Phoenix, Arizona.